There are currently 103 active clinical trials seeking participants for Glioblastoma research studies. The states with the highest number of trials for Glioblastoma participants are California, Ohio, New York and Texas.
Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma
NCT04817254
Recruiting
Background: Glioblastoma (GBM) is a type of malignant glioma. These cancers are nearly always fatal. People who develop these cancers get aggressive treatments. But the tumors almost always recur. Researchers want to study people with newly diagnosed disease to learn more. Objective: To study people with newly diagnosed GBM or gliosarcoma to look at the changes in immune cells in the blood of those who take ipilimumab and nivolumab, along with temozolomide. Eligibility: Adults ages 18 and o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/18/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Glioblastoma, Gliosarcoma, Malignant Glioma
Register for Updates
AZD1390 in Recurrent and Newly Diagnosed WHO Grade 4 Glioma Patients
NCT05182905
Recruiting
This is an open-label, single-center Phase 0/1b study that will enroll at least 27 participants with recurrent WHO Grade 4 Glioma requiring re-radiation and approximately 35 participants with newly-diagnosed WHO Grade 4 glioma (nGBM). The trial will be composed of a Phase 0 component (subdivided into Arms A - C), and an expansion Phase 1b. Patients with tumors demonstrating a positive PK response in the Phase 0 component of the study will be eligible to graduate to an expansion phase that combin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: St. Joseph's Hospital and Medical Center, Phoenix, Arizona
Conditions: Glioblastoma, Glioma, Glioblastoma Multiforme, Glioma, Malignant
Register for Updates
Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype
NCT03718767
Recruiting
Background: Gliomas are the most common malignant brain tumors. Some have certain changes (mutations) in the genes IDH1 or IDH2. If there are a high number of mutations in a tumor, it is called hypermutator phenotype (HMP). The drug nivolumab helps the immune system fight cancer. Researchers think it can be more effective in patients with IDH1 or IDH2 mutated gliomas with HMP. They will test gliomas with and without HMP. Objectives: To see if nivolumab stops tumor growth and prolongs the time... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Glioma, Glioblastoma, High Grage Glioma, Low Grade Glioma, Malignant Glioma
Register for Updates
Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma
NCT04555577
Recruiting
This phase I trial investigates the side effects and best dose of Peposertib, and to see how well it works in combination with radiation therapy in treating patients with newly diagnosed MGMT unmethylated glioblastoma or gliosarcoma. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Peposertib may further stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as temozolomide, work in different ways to stop th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/11/2025
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Glioblastoma, Gliosarcoma
Register for Updates
Oral Gallium Maltolate for the Treatment of Relapsed and Refractory Glioblastoma
NCT04319276
Recruiting
This is a phase 1 investigational study to assess the safety and preliminary efficacy of oral gallium maltolate (GaM) in participants with relapsed glioblastoma (GBM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Glioblastoma
Register for Updates
A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma
NCT06552260
Recruiting
This research study is studying troriluzole as a possible treatment for recurrent glioblastoma. The name of the study drug involved in this research study is: -Troriluzole (a tripeptide prodrug of riluzole)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts +2 locations
Conditions: Glioblastoma, Recurrent Glioblastoma, Brain Tumor
Register for Updates
Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
NCT05106296
Recruiting
Recent lab-based discoveries suggest that IDO (indoleamine 2,3-dioxygenase) and BTK (Bruton's tyrosine Kinase) form a closely linked metabolic checkpoint in tumor-associated antigen-presenting cells. The central clinical hypothesis for the GCC2020 study is that combining ibrutinib (BTK-inhibitor) with indoximod (IDO-inhibitor) during chemotherapy will synergistically enhance anti-tumor immune responses, leading to improvement in clinical response with manageable overlapping toxicity. GCC2020 is... Read More
Gender:
ALL
Ages:
Between 6 years and 25 years
Trial Updated:
03/05/2025
Locations: Augusta University, Georgia Cancer Center, Augusta, Georgia
Conditions: Ependymoma, Medulloblastoma, Glioblastoma, Primary Brain Tumor
Register for Updates
Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
NCT04049669
Recruiting
Indoximod was developed to inhibit the IDO (indoleamine 2,3-dioxygenase) enzymatic pathway, which is important in the natural regulation of immune responses. This potent immune suppressive mechanism has been implicated in regulating immune responses in settings as diverse as infection, tissue/organ transplant, autoimmunity, and cancer. By inhibiting the IDO pathway, we hypothesize that indoximod will improve antitumor immune responses and thereby slow the growth of tumors. The central clinical... Read More
Gender:
ALL
Ages:
Between 3 years and 21 years
Trial Updated:
03/05/2025
Locations: Augusta University, Georgia Cancer Center, Augusta, Georgia +4 locations
Conditions: Glioblastoma, Medulloblastoma, Ependymoma, Diffuse Intrinsic Pontine Glioma
Register for Updates
Testing the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
NCT05095376
Recruiting
This phase III trial compares the effect of adding lomustine to standard chemotherapy with temozolomide and radiation therapy versus temozolomide and radiation therapy alone in shrinking or stabilizing newly diagnosed MGMT methylated glioblastoma. MGMT methylated tumors are more likely to respond to temozolomide chemotherapy. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill tumor cells and slow down or stop tumor growth. Lomusti... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/04/2025
Locations: Fairbanks Memorial Hospital, Fairbanks, Alaska +372 locations
Conditions: Glioblastoma, Gliosarcoma
Register for Updates
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.
NCT05109728
Recruiting
A Dose Finding Study of \[177Lu\]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination with Standard of Care and in Recurrent Glioblastoma as a Single Agent
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
02/26/2025
Locations: Dana Farber Cancer Institute, Boston, Massachusetts +14 locations
Conditions: Glioblastoma
Register for Updates
Superselective Intra-arterial Cerebral Infusion of Temsirolimus in HGG
NCT05773326
Recruiting
This is a single-center, open-label, dose-escalating Phase 0 trial that will enroll participants with a confirmed diagnosed recurrent high-grade glioma (grade 3 or 4 per WHO criteria) targeting the mTOR pathway. Eligible participants will be administered a single infusion of temsirolimus through super-selective intra-arterial infusion or intravenous infusion. Participants will receive the study drug administration on the same day as the planned surgical resection of the tumor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: St. Joseph's Hospital and Medical Center, Phoenix, Arizona
Conditions: High Grade Glioma, Glioma, Glioma, Malignant, Glioblastoma
Register for Updates
NovoTTF Treatment Signatures in Glioblastoma Patients At Autopsy
NCT03194971
Recruiting
This study will assess whole brain samples from glioblastoma patients at autopsy to determine the underlying pathological signatures of tumor treatment fields at autopsy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/24/2025
Locations: Froedtert & the Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Glioblastoma
Register for Updates